Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Christian Ansprenger1, Emanuel Burri1

  • 11 Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, Kantonsspital Baselland.

Therapeutische Umschau. Revue Therapeutique
|February 1, 2019
PubMed
Summary
This summary is machine-generated.

Diagnosing and monitoring inflammatory bowel disease (IBD) involves multiple factors. Fecal calprotectin and therapeutic drug monitoring show promise for improved patient management and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a predictive model for postoperative body mass index and diabetes outcomes after metabolic bariatric surgery: retrospective cohort study.

BJS open·2026
Same author

The challenging diagnosis of sinistral portal hypertension in a patient with liver cirrhosis: a case report and literature review.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Referral pathway for adults with chronic cough in Switzerland from a Delphi-based consensus study.

Postgraduate medicine·2026
Same author

Sleeve gastrectomy versus Roux-en-Y-gastric bypass in patients with body mass index over 50 kg/m2: international multicentre cohort.

BJS open·2026
Same author

Modulation of Leukemic Blasts into Dendritic Cells (DC<sub>leu</sub>) and Their Role in Predicting Survival in Patients with AML and MDS.

Cancers·2026
Same author

Radiofrequency ablation (RFA) in unresectable pancreatic adenocarcinoma: meta-analysis & systematic review.

Surgical endoscopy·2024

Area of Science:

  • Gastroenterology
  • Clinical Medicine
  • Biomarker Research

Background:

  • Inflammatory Bowel Disease (IBD) diagnosis and monitoring rely on clinical, laboratory, endoscopic, and imaging data.
  • Therapeutic goals in IBD are shifting towards endoscopic and histologic targets like mucosal healing, though definitions remain inconsistent.
  • Patient tolerance for repeated endoscopies necessitates the investigation of non-invasive surrogate markers.

Purpose of the Study:

  • To review current diagnostic and monitoring strategies for Inflammatory Bowel Disease (IBD).
  • To evaluate the role of surrogate markers like fecal calprotectin in IBD management.
  • To assess the impact and application of therapeutic drug monitoring (TDM) in long-term IBD treatment.

Main Methods:

  • Comprehensive review of diagnostic modalities including clinical assessment, lab values, endoscopy, histology, and imaging.

Related Experiment Videos

  • Analysis of studies investigating fecal calprotectin as a surrogate marker for mucosal inflammation.
  • Examination of research on therapeutic drug monitoring (TDM) in IBD, including reactive and proactive approaches.

    • Main Results:

    • Fecal calprotectin demonstrates good correlation with endoscopic findings and has shown superiority in guiding therapy for Crohn's Disease when used for tight control.
    • Therapeutic drug monitoring (TDM), particularly for biologics, is increasingly utilized for long-term IBD management, with established protocols for reactive and proactive monitoring.
    • Current guidelines incorporate TDM, but further research is needed to confirm the benefits of tight monitoring strategies.

    Conclusions:

    • Fecal calprotectin serves as a valuable non-invasive marker for monitoring IBD activity and guiding treatment decisions.
    • Therapeutic drug monitoring (TDM) is a crucial component in the long-term management of IBD patients, especially those on biologic therapies.
    • Future research should focus on refining treatment targets and validating the long-term impact of intensified monitoring on IBD outcomes.